MedTrace Logo

A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

NCT02072096 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 192

Last updated 2019-10-09

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to compare the benefits and risks associated with the use of 2 treatment strategies to lower blood sugar in participants aged 65 and older with T2DM. One strategy is based on the use of oral and injectable medications that only reduce blood sugar (glucose) when it is high. The other strategy is based on non-glucose dependent agents. The trial will last up to 72 weeks for each participant.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Glimepiride

Administered orally

DRUG

Metformin

Administered orally

DRUG

Pioglitazone

Administered orally

DRUG

Acarbose

Administered orally

DRUG

Linagliptin

Administered orally

DRUG

Sitagliptin

Administered orally

DRUG

Liraglutide

Administered subcutaneously (SC)

DRUG

Insulin Glargine

Administered SC

DRUG

Exenatide once weekly (QW)

Administered SC

DRUG

Exenatide twice daily (BID)

Administered SC

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • United States
  • Austria
  • Germany
  • Puerto Rico
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02072096 on ClinicalTrials.gov